Concurrent chemoradiatherapy with raltitrexed and cisplatin in the treatment of moderate and advanced cervical cancer

doi:10.3877/cma.j.issn.1673-5250.2016.06.005

Objective

To investigate the efficacy and safety of concurrent chemoradiatherapy with raltitrexed and cisplatin in treatment of patients with moderate and advanced cervical cancer.

Methods

From January 2011 to December 2012, a total of 80 patients with moderate and advanced cervical cancer were selected as research subjects and they were randomly assigned to RP group (n=40, received concurrent chemoradiatherapy with raltitrexed and cisplatin treatment) and TP group (n=40, received concurrent chemoradiatherapy with paclitaxel and cisplatin treatment) by envelope method. The chemotherapy regimen of RP group was as follows: raltitrexed 3 mg/m² intravenous drip 15 min on day 1, and cisplatin 60 mg/m² intravenous drip 60 min on day 1. The chemotherapy regimen of TP group was as follows: paclitaxel 135 mg/m² intravenous drip 180 min on day 1, and cisplatin 60 mg/m² intravenous drip 60 min on day 2. The effective rate, adverse reactions rate, and overall survival (OS) rate and disease free survival (DFS) rate were observed and compared by statistical methods between two groups. This study was approved by the ethics committee of our hospital, and all patients signed the informed consent.

Results

①There were no significant differences between two groups in the age, Karnofsky performance status (KPS) score, body weight loss ratio, the maximum diameter of tumor, pathological type, Federation International of Gynecology and Obstetrics (FIGO) stage (P>0.05). ②The effective rates in RP group and TP group were 92.5% (38/40) and 90% (36/40), respectively, and there was no significant difference between them (χ²=0.734, P=0.675). ③The incidences of myelosuppression, rash, alopecia, muscle and joint pain, peripheral neuritis in RP group were 62.5% (25/40), 12.5% (5/40), 30.0% (12/40), 5.0% (2/40), 10.0% (4/40), respectively, and they were significantly lower than those in TP group 82.5% (33/40), 35.0% (14/40), 80.0% (32/40), 25.0% (10/40), 32.5% (13/40), respectively, and all the differences were statistically significant (χ²=4.013, P=0.045; χ²=5.591, P=0.018; χ²=20.202, P<0.001; χ²=6.275, P=0.012; χ²=6.050, P=0.014). There were no significant differences between two groups in gastrointestinal toxicity and liver dysfunction (P>0.05). ④There were no significant differences between two groups in OS curve and DFS curve (χ²=0.930, P=0.330; χ²=0.780, P=0.380).

Conclusions

Concurrent chemoradiatherapy with raltitrexed and cisplatin in the treatment of moderate and advanced cervical cancer is safe and effective. Its effect is similar to the effect of concurrent chemoradiatherapy with paclitaxel and cisplatin, and resulting in less adverse reactions.

Key words: Uterine cervical neoplasms, Radiotherapy, Drug therapy, Raltitrexed, Paclitaxel

表1 2组宫颈癌患者基本临床资料比较

组别	例数	年龄[岁，M(P₂₅～P₇₅)]	KPS评分[例数(%)]		体重下降[例数(%)]		肿瘤最大直径[例数(%)]
组别	例数	年龄[岁，M(P₂₅～P₇₅)]	≥70～80分	≥80分	<5%	≥5%	<4 cm	≥4 cm
RP组	40	47(39～66)	14(35.0)	26(65.0)	23(57.5)	17(42.5)	30(75.0)	10(25.0)
TP组	40	51(42～65)	17(42.5)	23(57.5)	25(62.5)	15(37.5)	28(70.0)	12(30.0)
检验值	?	Z＝－1.230	χ²＝0.475	?	χ²＝0.208	?	χ²＝0.251	?
P值	?	0.220	0.647	?	0.648	?	0.616	?
组别	例数	病理类型[例数(%)]			FIGO临床分期[例数(%)]
组别	例数	鳞癌	腺癌	鳞腺癌	Ⅱ_B	Ⅲ_A	Ⅲ_B	Ⅳ_A
RP组	40	29(72.5)	7(17.5)	4(10.0)	26(65.0)	8(20.0)	4(10.0)	2(5.0)
TP组	40	28(70.0)	9(22.5)	3(7.5)	25(57.5)	9(22.5)	3(7.5)	3(7.5)
检验值	?	χ²＝0.482			χ²＝0.421
P值	?	0.874			0.936

表1 2组宫颈癌患者基本临床资料比较

组别	例数	年龄[岁，M(P₂₅～P₇₅)]	KPS评分[例数(%)]		体重下降[例数(%)]		肿瘤最大直径[例数(%)]
组别	例数	年龄[岁，M(P₂₅～P₇₅)]	≥70～80分	≥80分	<5%	≥5%	<4 cm	≥4 cm
RP组	40	47(39～66)	14(35.0)	26(65.0)	23(57.5)	17(42.5)	30(75.0)	10(25.0)
TP组	40	51(42～65)	17(42.5)	23(57.5)	25(62.5)	15(37.5)	28(70.0)	12(30.0)
检验值	?	Z＝－1.230	χ²＝0.475	?	χ²＝0.208	?	χ²＝0.251	?
P值	?	0.220	0.647	?	0.648	?	0.616	?
组别	例数	病理类型[例数(%)]			FIGO临床分期[例数(%)]
组别	例数	鳞癌	腺癌	鳞腺癌	Ⅱ_B	Ⅲ_A	Ⅲ_B	Ⅳ_A
RP组	40	29(72.5)	7(17.5)	4(10.0)	26(65.0)	8(20.0)	4(10.0)	2(5.0)
TP组	40	28(70.0)	9(22.5)	3(7.5)	25(57.5)	9(22.5)	3(7.5)	3(7.5)
检验值	?	χ²＝0.482			χ²＝0.421
P值	?	0.874			0.936

表2 2组宫颈癌患者不良反应发生情况比较[例数(%)]

组别	例数	恶心						呕吐
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	9(22.5)	23(57.5)	7(17.5)	1(2.5)	0(0)	31(77.5)	25(62.5)	9(22.5)	6(15.0)	1(2.5)	0(0)	15(37.5)
TP组	40	8(20.0)	24(60.0)	7(17.5)	1(2.5)	0(0)	32(80.0)	23(57.5)	9(22.5)	7(17.5)	1(2.5)	0(0)	17(42.5)
χ²值	?	－	－	－	－	－	0.075	－	－	－	－	－	0.208
P值	?	－	－	－	－	－	0.785	－	－	－	－	－	0.648
组别	例数	腹泻						食欲下降
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	25(62.5)	9(22.5)	5(12.5)	1(2.5)	0(0)	15(37.5)	17(42.5)	16(40.0)	7(17.5)	0(0)	0(0)	23(57.5)
TP组	40	28(70.0)	8(20.0)	4(10.0)	0(0)	0(0)	12(30.0)	16(40.0)	17(42.5)	7(17.5)	1(2.5)	0(0)	24(60.0)
χ²值	?	－	－	－	－	－	0.503	－	－	－	－	－	0.052
P值	?	－	－	－	－	－	0.478	－	－	－	－	－	0.82
组别	例数	骨髓抑制						肝功能损害
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	15(37.5)	13(32.5)	11(27.5)	4(10.0)	0(0)	25(62.5)	35(87.5)	5(12.5)	1(2.5)	0(0)	0(0)	5(12.5)
TP组	40	7(17.5)	13(32.5)	12(30.0)	7(17.5)	1(2.5)	33(82.5)	34(85.0)	6(15.0)	1(2.5)	0(0)	0(0)	6(15.0)
χ²值	?	－	－	－	－	－	4.013	－	－	－	－	－	0.105
P值	?	－	－	－	－	－	0.045	－	－	－	－	－	0.745
组别	例数	皮疹						脱发
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	35(87.5)	4(10.0)	1(2.5)	0(0)	0(0)	5(12.5)	28(70.0)	12(30.0)	0(0)	0(0)	0(0)	12(30.0)
TP组	40	26(65.0)	8(20.0)	4(10.0)	2(5.0)	0(0)	14(35.0)	8(20.0)	15(37.5)	17(42.5)	0(0)	0(0)	32(80.0)
χ²值	?	－	－	－	－	－	5.591	－	－	－	－	－	20.202
P值	?	－	－	－	－	－	0.018	－	－	－	－	－	0.000
组别	例数	肌肉和关节疼痛						外周神经炎
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	38(95.0)	1(2.5)	1(2.5)	0(0)	0(0)	2(5.0)	36(90.0)	2(5.0)	2(5.0)	0(0)	0(0)	4(10.0)
TP组	40	30(75.0)	6(15.0)	4(10.0)	0(0)	0(0)	10(25.0)	27(67.5)	6(15.0)	5(12.5)	2(5.0)	0(0)	13(32.5)
χ²值	?	－	－	－	－	－	6.275	－	－	－	－	－	6.050
P值	?	－	－	－	－	－	0.012	－	－	－	－	－	0.014

表2 2组宫颈癌患者不良反应发生情况比较[例数(%)]

组别	例数	恶心						呕吐
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	9(22.5)	23(57.5)	7(17.5)	1(2.5)	0(0)	31(77.5)	25(62.5)	9(22.5)	6(15.0)	1(2.5)	0(0)	15(37.5)
TP组	40	8(20.0)	24(60.0)	7(17.5)	1(2.5)	0(0)	32(80.0)	23(57.5)	9(22.5)	7(17.5)	1(2.5)	0(0)	17(42.5)
χ²值	?	－	－	－	－	－	0.075	－	－	－	－	－	0.208
P值	?	－	－	－	－	－	0.785	－	－	－	－	－	0.648
组别	例数	腹泻						食欲下降
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	25(62.5)	9(22.5)	5(12.5)	1(2.5)	0(0)	15(37.5)	17(42.5)	16(40.0)	7(17.5)	0(0)	0(0)	23(57.5)
TP组	40	28(70.0)	8(20.0)	4(10.0)	0(0)	0(0)	12(30.0)	16(40.0)	17(42.5)	7(17.5)	1(2.5)	0(0)	24(60.0)
χ²值	?	－	－	－	－	－	0.503	－	－	－	－	－	0.052
P值	?	－	－	－	－	－	0.478	－	－	－	－	－	0.82
组别	例数	骨髓抑制						肝功能损害
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	15(37.5)	13(32.5)	11(27.5)	4(10.0)	0(0)	25(62.5)	35(87.5)	5(12.5)	1(2.5)	0(0)	0(0)	5(12.5)
TP组	40	7(17.5)	13(32.5)	12(30.0)	7(17.5)	1(2.5)	33(82.5)	34(85.0)	6(15.0)	1(2.5)	0(0)	0(0)	6(15.0)
χ²值	?	－	－	－	－	－	4.013	－	－	－	－	－	0.105
P值	?	－	－	－	－	－	0.045	－	－	－	－	－	0.745
组别	例数	皮疹						脱发
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	35(87.5)	4(10.0)	1(2.5)	0(0)	0(0)	5(12.5)	28(70.0)	12(30.0)	0(0)	0(0)	0(0)	12(30.0)
TP组	40	26(65.0)	8(20.0)	4(10.0)	2(5.0)	0(0)	14(35.0)	8(20.0)	15(37.5)	17(42.5)	0(0)	0(0)	32(80.0)
χ²值	?	－	－	－	－	－	5.591	－	－	－	－	－	20.202
P值	?	－	－	－	－	－	0.018	－	－	－	－	－	0.000
组别	例数	肌肉和关节疼痛						外周神经炎
组别	例数	1级	2级	3级	4级	5级	合计	1级	2级	3级	4级	5级	合计
RP组	40	38(95.0)	1(2.5)	1(2.5)	0(0)	0(0)	2(5.0)	36(90.0)	2(5.0)	2(5.0)	0(0)	0(0)	4(10.0)
TP组	40	30(75.0)	6(15.0)	4(10.0)	0(0)	0(0)	10(25.0)	27(67.5)	6(15.0)	5(12.5)	2(5.0)	0(0)	13(32.5)
χ²值	?	－	－	－	－	－	6.275	－	－	－	－	－	6.050
P值	?	－	－	－	－	－	0.012	－	－	－	－	－	0.014

图1 2组宫颈癌患者总生存曲线比较

图2 2组宫颈癌患者无病生存曲线比较

[1]	Kim TE, Park BJ, Kwack HS, et al. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation[J]. J Obstet Gynaecol Res，2012，38(11)：1315-1320.
[2]	Lee TS, Kang SB, Kim YT, et al. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study[J]. Int J Radiat Oncol Biol Phys，2013，86(2)：304-310.
[3]	Nagai Y, Toita T, Wakayama A, et al. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix[J]. Anticancer Res，2012，32(4)：1475-1479.
[4]	Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history[J]. Eur J Cancer，2013，49(10)：2303-2310.
[5]	Li XY, Liu L, Xie XM, et al. The role of raltitrexed/cisplatin with concurrent radiation therapy in treating advanced cervical cancer[J]. Eur Rev Med Pharmacol Sci，2014，18(22)：3491-3496.
[6]	卜祥兆，刘凌，周云. 子宫颈癌外照射范围的临床探讨[J]. 中华放射肿瘤学杂志，2010，19(3)：221-222.
[7]	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors[J]. J Natl Cancer Inst, 2000, 92(3): 205-216.
[8]	Ishitsuka R, Miyazaki J, Ichioka D, et al. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients[J/OL]. Clin Exp Nephrol, (2016-08-26)[2016-09-28]. URL
[9]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2)：87-108.
[10]	阳志军，陈艳丽，李力，等. 不同治疗模式对Ⅱ_B期宫颈癌患者预后和生活质量的影响[J]. 肿瘤防治研究，2014, 41(9)：1021-1025.
[11]	Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis[J]. Cochrane Database Syst Rev，2010, 1：CD008285.
[12]	Avallone A, Di Gennaro E, Silvestro L, et al. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed[J]. Expert Opin Drug Saf, 2014, 13(1): 113-129.
[13]	Zhao C, Fan L, Qi F, et al. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma[J]. Anticancer Drugs，2016，27(7)：689-694.
[14]	Ransom D, Wilson K, Fournier M, et al. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines[J]. Ann Oncol，2014，25(1)：117-121.
[15]	Gaafar P, Sallam YA, Shafik HE, et al. Impact of New Chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma[J]. Gulf J Oncolog，2014，1(16)：56-63.
[16]	Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer[J]. Anticancer Drugs，2014，25(10)：1122-1128.
[17]	Wilson KS, Fitzgerald CA, Barnett JB, et al. Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience[J]. Cancer Invest，2007，25(8)：711-714.
[18]	Judson I, Maughan T, Beale P, et al. Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)[J]. Br J Cancer，1998，78(9)：1188-1193.
[19]	ZalcbergJ. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer[J]. Anticancer Drugs，1997，8(Suppl 2)：S17-S22.
[20]	Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group[J]. J Clin Oncol，1998，16(9)：2943-2952.

[1]	Xuebing Shi, Yingdong Xie, Ni Xie, Chaoli Xu, Bin Yang, Guo Sun. Acoustic radiation force imaging for evaluating efficacy of radiotherapy in unresectable hepatocellular carcinoma patients with portal vein tumor thrombus[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(08): 778-784.
[2]	Jiechun Shi, Ziyu Fan, Yan Xing. Early warning efficiency of different screening methods on cervical adenocarcinoma in situ[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2024, 20(05): 575-581.
[3]	Daiqin Li, Peijie Liu. Value of dynamic enhanced magnetic resonance imaging in evaluating the efficacy and prognosis of middle and advanced low rectal cancer after concurrent chemoradiotherapy[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 100-103.
[4]	DaRebai· ReDati, Lin Liu, Weimin Zhao, Tao Meng, Cheng Lei, Bo Jin, Jianjun Bi, Xinyu Li, Haijiang Wang. Clinical observation of lateral lymph node dissection after neoadjuvant chemoradiotherapy for middle and low rectal cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 415-418.
[5]	Weizhou Wu, Qiongren Wang, Xiongyu Zhan, Mingxing Zheng, Yaxian Li. Multidisciplinary consultation on difficult cases in Guangdong Urological Association (Phase 16): sarcomatoid renal cell carcinoma of the left kidney[J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 525-529.
[6]	Guiping Zhang, Yonglin Qiu, Qiting Zhan, Ledong Sun. Prognostic significance of serum Ape1/Ref-1 for the radioactive lung injury in patients with advanced non-small cell lung cancer[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2024, 17(04): 519-523.
[7]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition）[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[8]	Zhexue Wang, Junge Bai, Dedi Jiang, Yuegang Li, Ming Yang, Haipeng Chen, Zheng Liu. Factors influencing tumor regression grade and prognosis in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(05): 368-374.
[9]	Yutian Tang, Yanzhi Wang, Yi Wang, Yimin Ren, Yanshan Zhang, Wenxue Zhao, Fang Wang, Wenyuan Yang. Safety analysis of high-frequency oscillatory ventilation to control respiratory movement in patients with thoracic and abdominal tumors treated with carbon ion precision therapy[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(04): 344-350.
[10]	Wei Duan, Fei Liu, Guangyuan Xu, Yuhao Cheng, Xing Chen. Effect of different dosimetric parameters of intensity modulated radiotherapy plans for esophageal cancer on the occurrence and severity of radiation pneumonia[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(04): 320-324.
[11]	Haiqiang Chu, Yuanyou Yang, Gang Ren. Progress in research of radiotherapy-based combined therapy for pancreatic cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(04): 392-396.
[12]	Xinying Zheng, Huiyong Zhang, Xing Huang, Lei Qiu, Qingliang Fang, Zhenhui Lu, Lei Wang. Dual regulatory role of TGF-β in radiaotherapy[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(03): 309-314.
[13]	Pu Li, Xiujie Sheng. Management of pregnancy complicated with cervical cancer[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2024, 13(04): 202-208.
[14]	Qiuyi Chen, Xi Lin, Zhenyin Liu. Advances in the molecular mechanism of lymphatic malformations[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2024, 12(04): 374-379.
[15]	Ruifang Hu, Lijuan Fan. Research progress on diagnostic biomarkers of esophageal squamous intraepithelial neoplasia and status of non-endoscopic treatment[J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(04): 281-286.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export